


SUMMARY

The present disclosure is directed to benzenesulfonamide compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions of the disclosure for the treatment of diseases or conditions associated with the activity of voltage-gated sodium channels, particularly, $\text{Na}_v1.6$ activity, such as epilepsy and/or epileptic seizure disorder.

Accordingly, in one example, this disclosure is directed to benzenesulfonamide compounds of formula (I):



10 wherein:

n is 1, 2, 3;

m is 1, 2, 3 or 4;

X is a direct bond or $-\text{C}(\text{R}^9)\text{R}^{10}-$;

Y is a direct bond or $-\text{C}(\text{R}^{11})\text{R}^{12}-$;

15 R^1 is hydrogen, alkyl, $-\text{R}^{17}-\text{OR}^{14}$, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted *N*-heterocyclyl, an optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an optionally substituted *S*-heteroaryl;

R^2 is an optionally substituted 5-membered *N*-heteroaryl or an optionally substituted 6-membered *N*-heteroaryl;

20 R^3 is $-\text{O}-$ or $-\text{N}(\text{R}^{13})-$;

R^4 and R^5 are each independently hydrogen, alkyl, haloalkyl, optionally substituted

cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

25

or R^4 and R^1 , together with the carbon to which they are attached, form an optionally substituted cycloalkyl, an optionally substituted heterocyclyl or an optionally substituted aryl, and R^5 , if present, is hydrogen, alkyl, haloalkyl, optionally

30 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally

substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

each R⁶ is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, -OR¹⁴ or
 5 optionally substituted cycloalkyl;

R⁷ is alkyl, halo, haloalkyl, cyano or -OR¹⁴;

each R⁸ is independently hydrogen, alkyl, halo, haloalkyl or -OR¹⁴;

or two R⁸'s, together with the carbon to which they are both attached, may form an
 optionally substituted cycloalkyl;

10 R⁹, R¹⁰, R¹¹ and R¹² are each independently hydrogen, alkyl, haloalkyl or -OR¹⁴;

or R⁹ and R¹¹ form an optionally substituted alkylene chain and R¹⁰ and R¹² are as
 defined above; and

R¹³ is hydrogen, alkyl or haloalkyl;

each R¹⁴ are each independently hydrogen, alky, haloalkyl, optionally substituted aryl
 15 or optionally substituted aralkyl; and

R¹⁷ is a direct bond or an optionally substituted alkylene chain;


as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

provided that when R³ is -O-, R² is not optionally substituted thiadiazolyl.

20 The compounds of the disclosure, which are compounds of formula (I), as
 described above, as individual stereoisomers, enantiomers or tautomers thereof or
 mixtures thereof; or as pharmaceutically acceptable salts, solvates or prodrugs thereof,
 are useful in treating diseases or conditions associated with voltage-gated sodium
 channels, preferably Na_v1.6. Preferably, the compounds of the disclosure are Na_v1.6
 25 inhibitors. More preferably, the compounds of the disclosure show selectivity of
 inhibiting Na_v1.6 as compared with inhibiting Na_v1.5 and/or Na_v1.1. Without wishing to
 be bound by theory, such selectivity is thought to advantageously reduce any side
 effects which may be associated with the inhibition of Na_v1.5 and/or Na_v1.1.

In a first aspect, the present disclosure refers to a compound of formula (I):



30

as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or
a pharmaceutically acceptable salt or solvate thereof, wherein:

n is 1, 2, or 3;
m is 1, 2, 3 or 4;

5 X is a direct bond or $-C(R^9)R^{10}-$;
Y is a direct bond or $-C(R^{11})R^{12}-$;
R¹ is alkyl, $-R^{17}-OR^{14}$, an optionally substituted cycloalkyl, an optionally substituted aryl,
an optionally substituted aralkyl, an optionally substituted *N*-heterocyclyl, an
optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an
10 optionally substituted *S*-heteroaryl;

R² is an optionally substituted 5-membered *N*-heteroaryl or an optionally substituted
6-membered *N*-heteroaryl;

R³ is $-O-$ or $-N(R^{13})-$;

R⁴ and R⁵ are each independently hydrogen, alkyl, haloalkyl, optionally substituted
15 cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted heterocyclyl, optionally
substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally
substituted heteroarylalkyl;

or R⁴ and R¹, together with the carbon to which they are attached, form an optionally
20 substituted cycloalkyl, or an optionally substituted heterocyclyl, and R⁵, is
hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally
substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted
heteroaryl or optionally substituted heteroarylalkyl;

25 each R⁶ is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, $-OR^{14}$ or
optionally substituted cycloalkyl;

R⁷ is alkyl, halo, haloalkyl, cyano or $-OR^{14}$;

each R⁸ is independently hydrogen, alkyl, halo, haloalkyl or $-OR^{14}$;

or two R⁸'s, together with the carbon to which they are both attached, may form an
30 optionally substituted cycloalkyl;

R⁹, R¹⁰, R¹¹ and R¹² are each independently hydrogen, alkyl, haloalkyl or $-OR^{14}$;

or R⁹ and R¹¹ form an optionally substituted alkylene chain; and

R¹³ is hydrogen, alkyl or haloalkyl;

each R¹⁴ are each independently hydrogen, alky, haloalkyl, optionally substituted aryl
35 or optionally substituted aralkyl; and

R^{17} is a direct bond or an optionally substituted alkylene chain;
 provided that when R^3 is -O-, R^2 is not optionally substituted thiadiazolyl;
 wherein:
 the term *N*-heterocyclyl refers to a heterocyclyl radical containing at least one nitrogen,
 5 wherein the point of attachment of the *N*-heterocyclyl to the rest of the molecule
 can be through a nitrogen atom or a carbon atom in the *N*-heterocyclyl;
 the term *N*-heteroaryl refers to a heteroaryl radical containing at least one nitrogen,
 wherein the point of attachment of the *N*-heteroaryl to the rest of the molecule
 can be through a nitrogen atom or a carbon atom in the *N*-heteroaryl;
 10 the term *O*-heteroaryl refers to a heteroaryl radical wherein the only heteroatoms
 present are oxygen, wherein the point of attachment of the *O*-heteroaryl to the
 rest of the molecule is through a carbon atom in the *O*-heteroaryl radical;
 the term *S*-heteroaryl refers to a heteroaryl radical wherein the only heteroatoms
 present are sulfur, wherein the point of attachment of the *S*-heteroaryl to the
 15 rest of the molecule is through a carbon atom in the *S*-heteroaryl radical;
 each optionally substituted alkylene chain and the alkylene chain radical of each
 optionally substituted aralkyl, cycloalkylalkyl, heterocyclylalkyl, and
 heteroarylalkyl may be substituted one of the following groups: alkyl, alkenyl,
 halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo,
 20 trimethylsilanyl, $-OR^{20}$, $-OC(O)-R^{20}$, $-N(R^{20})_2$, $-C(O)R^{20}$, $-C(O)OR^{20}$, $-$
 $C(O)N(R^{20})_2$, $-N(R^{20})C(O)OR^{22}$, $-N(R^{20})C(O)R^{22}$, $-N(R^{20})S(O)_pR^{22}$, $-S(O)_pOR^{22}$, $-$
 $S(O)_tR^{22}$, and $-S(O)_pN(R^{20})_2$;
 each optionally substituted cycloalkyl and the cycloalkyl radical of each optionally
 substituted cycloalkylalkyl may be optionally substituted by one or more
 25 substituents independently selected from the group consisting of alkyl, alkenyl,
 halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl,
 cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-$
 OR^{20} , $-R^{21}-OC(O)-R^{20}$, $-R^{21}-N(R^{20})_2$, $-R^{21}-C(O)R^{20}$, $-R^{21}-C(O)OR^{20}$, $-R^{21}-$
 $C(O)N(R^{20})_2$, $-R^{21}-N(R^{20})C(O)OR^{22}$, $-R^{21}-N(R^{20})C(O)R^{22}$, $-R^{21}-N(R^{20})S(O)_pR^{22}$, $-$
 30 $R^{21}-N=C(OR^{20})R^{20}$, $-R^{21}-S(O)_pOR^{22}$, $-R^{21}-S(O)_tR^{22}$, and $-R^{21}-S(O)_pN(R^{20})_2$;
 each optionally substituted aryl and the aryl radical of each optionally substituted
 aralkyl, may be optionally substituted by one or more substituents
 independently selected from the group consisting of alkyl, alkenyl, halo,
 haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
 35 heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-OR^{20}$, $-R^{21}-$

OC(O)-R^{20} , $-\text{R}^{21}-\text{N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{C(O)R}^{20}$, $-\text{R}^{21}-\text{C(O)OR}^{20}$, $-\text{R}^{21}-\text{C(O)N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)OR}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)R}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{S(O)}_p\text{R}^{22}$ (where p is 1 to 2), $-\text{R}^{21}-\text{N}=\text{C}(\text{OR}^{20})\text{R}^{20}$, $-\text{R}^{21}-\text{S(O)}_p\text{OR}^{22}$, $-\text{R}^{21}-\text{S(O)}_t\text{R}^{22}$, and $-\text{R}^{21}-\text{S(O)}_p\text{N}(\text{R}^{20})_2$;

each optionally substituted heterocyclyl, optionally substituted N-heterocyclyl, and the

5 heterocyclyl radical of each optionally substituted heterocyclylalkyl may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-\text{R}^{21}-\text{OR}^{20}$, $-\text{R}^{21}-\text{OC(O)-R}^{20}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{C(O)R}^{20}$, $-\text{R}^{21}-\text{C(O)OR}^{20}$, $-\text{R}^{21}-\text{C(O)N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)OR}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)R}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{S(O)}_p\text{R}^{22}$ (where p is 1 to 2), $-\text{R}^{21}-\text{N}=\text{C}(\text{OR}^{20})\text{R}^{20}$, $-\text{R}^{21}-\text{S(O)}_p\text{OR}^{22}$ (where p is 1 to 2), $-\text{R}^{21}-\text{S(O)}_t\text{R}^{22}$ (where t is 0 to 2), and $-\text{R}^{21}-\text{S(O)}_p\text{N}(\text{R}^{20})_2$; and

10 each optionally substituted heteroaryl, optionally substituted N-heteroaryl, optionally substituted O-heteroaryl, optionally substituted S-heteroaryl, and the heteroaryl radical of each heteroarylalkyl may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, thioxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-\text{R}^{21}-\text{OR}^{20}$, $-\text{R}^{21}-\text{OC(O)-R}^{20}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{C(O)R}^{20}$, $-\text{R}^{21}-\text{C(O)OR}^{20}$, $-\text{R}^{21}-\text{C(O)N}(\text{R}^{20})_2$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)OR}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{C(O)R}^{22}$, $-\text{R}^{21}-\text{N}(\text{R}^{20})\text{S(O)}_p\text{R}^{22}$, $-\text{R}^{21}-\text{N}=\text{C}(\text{OR}^{20})\text{R}^{20}$, $-\text{R}^{21}-\text{S(O)}_p\text{OR}^{22}$, $-\text{R}^{21}-\text{S(O)}_t\text{R}^{22}$, and $-\text{R}^{21}-\text{S(O)}_p\text{N}(\text{R}^{20})_2$;

15 20 wherein:

each p is independently 1 to 2;

25 each t is independently 0 to 2;

each R^{20} is independently hydrogen, C_{1-12} alkyl, C_{1-12} haloalkyl, C_{3-15} cycloalkyl, cycloalkylalkyl, C_{6-18} aryl, aralkyl, 3-18 membered heterocyclyl, heterocyclylalkyl, 5-14 membered heteroaryl, or heteroarylalkyl;

each R^{21} is independently a direct bond or a straight or branched C_{1-12} alkylene chain;


30 and

each R^{22} is C_{1-12} alkyl, C_{1-12} haloalkyl, C_{3-15} cycloalkyl, cycloalkylalkyl, C_{6-18} aryl, aralkyl, 3-18 membered heterocyclyl, heterocyclylalkyl, 5-14 membered heteroaryl or heteroarylalkyl.

In a second aspect, the present disclosure refers to a compound, which is (S)-


35 4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-

yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In a third aspect, the present disclosure refers to a compound, which is (S)-4-
5 ((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In a fourth aspect, the present disclosure refers to a compound, which is (S)-
10 2,6-difluoro-3-methyl-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In fifth aspect, the present disclosure refers to a compound, which is (S)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-2,6-difluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In a sixth aspect, the present disclosure refers to a compound, which is (S)-3-chloro-2,6-difluoro-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In a seventh aspect, the present disclosure refers to a compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-N-(isothiazol-3-yl)-5-methylbenzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In an eighth aspect, the present disclosure refers to a compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-N-(isothiazol-3-yl)-3-methylbenzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

In a ninth aspect, the present disclosure refers to a compound, which is (S)-4-
 5 ((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-N-(6-fluoropyridin-2-yl)-3-
 methylbenzenesulfonamide, represented by the formula:



or a pharmaceutically acceptable salt or solvate thereof.

In a tenth aspect, the present disclosure refers to a compound, which is (S)-4-
 10 ((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-3-methyl-N-(thiazol-4-
 yl)benzenesulfonamide, represented by the formula:



or a pharmaceutically acceptable salt or solvate thereof.

In another example, the disclosure provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

In an eleventh aspect, the present disclosure refers to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof.

In another example, the disclosure provides methods for the treatment of epilepsy and/or epileptic seizure disorder in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically

effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.

In another example, the present disclosure provides a method for treating or lessening the severity of a disease, condition, or disorder in a mammal where activation or hyperactivity of $\text{Na}_v1.6$ is implicated in the disease, condition or disorder, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.

In another example, the disclosure provides methods of treating or ameliorating, but not preventing, epilepsy and/or epileptic seizure disorder in a mammal, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.

In another example, the disclosure provides pharmaceutical therapy in combination with one or more other compounds of the disclosure or one or more other accepted therapies or as any combination thereof to increase the potency of an existing or future drug therapy or to decrease the adverse events associated with the accepted therapy. In one example, the present disclosure relates to a pharmaceutical composition combining compounds of the present disclosure with established or future therapies for the indications listed herein.

In another example, this disclosure is directed to methods of selectively inhibiting a first voltage-gated sodium channel in a mammal over a second voltage-gated sodium channel, wherein the method comprises administering to the mammal a inhibitory amount of a compound of the disclosure, as set forth above, as a
5 stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition comprising a inhibitory amount of a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically
10 acceptable excipient.

In a twelfth aspect, the present disclosure refers to a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof, for
15 use in selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal.

In a thirteenth aspect, the present disclosure refers to use of a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of
20 the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal

In another example, this disclosure is directed to the use of the compounds of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof
25 or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the disclosure, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of
30 a disease or condition associated with the activity of a voltage-gated sodium channel, preferably $Na_v1.6$, in a mammal and preferably wherein the disease or condition is epilepsy and/or epileptic seizure disorder.

In a fourteenth aspect, the present disclosure refers to a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof, for use in treating a disease or a condition associated with Na_v1.6 activity in a mammal, wherein the disease or condition is epilepsy and/or epileptic seizure disorder.

In a fifteenth aspect, the present disclosure refers to use of a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a disease or a condition associated with Na_v1.6 activity in a mammal, wherein the disease or condition is epilepsy and/or epileptic seizure disorder

In a sixteenth aspect, the present disclosure refers to an *in vitro* method of decreasing ion flux through Na_v1.6 in a mammalian cell, wherein the method comprises contacting the cell with a compound of the first aspect, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of the second to tenth aspects, or a pharmaceutically acceptable salt or solvate thereof.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS


Certain chemical groups named herein may be preceded by a shorthand notation indicating the total number of carbon atoms that are to be found in the indicated chemical group. For example; C₇-C₁₂alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms, and C₄-C₁₂cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms. The total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described.

In addition to the foregoing, as used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated:

"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms, more preferably one to six

CLAIMS

1. A compound of formula (I):



as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or
a pharmaceutically acceptable salt or solvate thereof, wherein:

n is 1, 2, or 3;

m is 1, 2, 3 or 4;

X is a direct bond or $-C(R^9)R^{10}-$;

Y is a direct bond or $-C(R^{11})R^{12}-$;

R^1 is alkyl, $-R^{17}-OR^{14}$, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted *N*-heterocyclyl, an optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an optionally substituted *S*-heteroaryl;

R^2 is an optionally substituted 5-membered *N*-heteroaryl or an optionally substituted 6-membered *N*-heteroaryl;

R^3 is $-O-$ or $-N(R^{13})-$;

R^4 and R^5 are each independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

or R^4 and R^1 , together with the carbon to which they are attached, form an optionally substituted cycloalkyl, or an optionally substituted heterocyclyl, and R^5 , is hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;

each R^6 is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, $-OR^{14}$ or optionally substituted cycloalkyl;

R^7 is alkyl, halo, haloalkyl, cyano or $-OR^{14}$;
 each R^8 is independently hydrogen, alkyl, halo, haloalkyl or $-OR^{14}$;
 or two R^8 's, together with the carbon to which they are both attached, may form an optionally substituted cycloalkyl;
 R^9 , R^{10} , R^{11} and R^{12} are each independently hydrogen, alkyl, haloalkyl or $-OR^{14}$;
 or R^9 and R^{11} form an optionally substituted alkylene chain; and
 R^{13} is hydrogen, alkyl or haloalkyl;
 each R^{14} are each independently hydrogen, alky, haloalkyl, optionally substituted aryl or optionally substituted aralkyl; and
 R^{17} is a direct bond or an optionally substituted alkylene chain;
 provided that when R^3 is $-O-$, R^2 is not optionally substituted thiadiazolyl;
 wherein:
 the term *N*-heterocyclyl refers to a heterocyclyl radical containing at least one nitrogen, wherein the point of attachment of the *N*-heterocyclyl to the rest of the molecule can be through a nitrogen atom or a carbon atom in the *N*-heterocyclyl;
 the term *N*-heteroaryl refers to a heteroaryl radical containing at least one nitrogen, wherein the point of attachment of the *N*-heteroaryl to the rest of the molecule can be through a nitrogen atom or a carbon atom in the *N*-heteroaryl;
 the term *O*-heteroaryl refers to a heteroaryl radical wherein the only heteroatoms present are oxygen, wherein the point of attachment of the *O*-heteroaryl to the rest of the molecule is through a carbon atom in the *O*-heteroaryl radical;
 the term *S*-heteroaryl refers to a heteroaryl radical wherein the only heteroatoms present are sulfur, wherein the point of attachment of the *S*-heteroaryl to the rest of the molecule is through a carbon atom in the *S*-heteroaryl radical;
 each optionally substituted alkylene chain and the alkylene chain radical of each optionally substituted aralkyl, cycloalkylalkyl, heterocyclylalkyl, and heteroarylalkyl may be substituted one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, $-OR^{20}$, $-OC(O)-R^{20}$, $-N(R^{20})_2$, $-C(O)R^{20}$, $-C(O)OR^{20}$, $-C(O)N(R^{20})_2$, $-N(R^{20})C(O)OR^{22}$, $-N(R^{20})C(O)R^{22}$, $-N(R^{20})S(O)_pR^{22}$, $-S(O)_pOR^{22}$, $-S(O)_pR^{22}$, and $-S(O)_pN(R^{20})_2$;
 each optionally substituted cycloalkyl and the cycloalkyl radical of each optionally substituted cycloalkylalkyl may be optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl,

cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-OR^{20}$, $-R^{21}-OC(O)-R^{20}$, $-R^{21}-N(R^{20})_2$, $-R^{21}-C(O)R^{20}$, $-R^{21}-C(O)OR^{20}$, $-R^{21}-C(O)N(R^{20})_2$, $-R^{21}-N(R^{20})C(O)OR^{22}$, $-R^{21}-N(R^{20})C(O)R^{22}$, $-R^{21}-N(R^{20})S(O)_pR^{22}$, $-R^{21}-N=C(OR^{20})R^{20}$, $-R^{21}-S(O)_pOR^{22}$, $-R^{21}-S(O)_tR^{22}$, and $-R^{21}-S(O)_pN(R^{20})_2$;

each optionally substituted aryl and the aryl radical of each optionally substituted aralkyl, may be optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-OR^{20}$, $-R^{21}-OC(O)-R^{20}$, $-R^{21}-N(R^{20})_2$, $-R^{21}-C(O)R^{20}$, $-R^{21}-C(O)OR^{20}$, $-R^{21}-C(O)N(R^{20})_2$, $-R^{21}-N(R^{20})C(O)OR^{22}$, $-R^{21}-N(R^{20})C(O)R^{22}$, $-R^{21}-N(R^{20})S(O)_pR^{22}$ (where p is 1 to 2), $-R^{21}-N=C(OR^{20})R^{20}$, $-R^{21}-S(O)_pOR^{22}$, $-R^{21}-S(O)_tR^{22}$, and $-R^{21}-S(O)_pN(R^{20})_2$;

each optionally substituted heterocyclyl, optionally substituted N-heterocyclyl, and the heterocyclyl radical of each optionally substituted heterocyclylalkyl may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-OR^{20}$, $-R^{21}-OC(O)-R^{20}$, $-R^{21}-N(R^{20})_2$, $-R^{21}-C(O)R^{20}$, $-R^{21}-C(O)OR^{20}$, $-R^{21}-C(O)N(R^{20})_2$, $-R^{21}-N(R^{20})C(O)OR^{22}$, $-R^{21}-N(R^{20})C(O)R^{22}$, $-R^{21}-N(R^{20})S(O)_pR^{22}$ (where p is 1 to 2), $-R^{21}-N=C(OR^{20})R^{20}$, $-R^{21}-S(O)_pOR^{22}$ (where p is 1 to 2), $-R^{21}-S(O)_tR^{22}$ (where t is 0 to 2), and $-R^{21}-S(O)_pN(R^{20})_2$; and

each optionally substituted heteroaryl, optionally substituted N-heteroaryl, optionally substituted O-heteroaryl, optionally substituted S-heteroaryl, and the heteroaryl radical of each heteroarylalkyl may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, thioxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, $-R^{21}-OR^{20}$, $-R^{21}-OC(O)-R^{20}$, $-R^{21}-N(R^{20})_2$, $-R^{21}-C(O)R^{20}$, $-R^{21}-C(O)OR^{20}$, $-R^{21}-C(O)N(R^{20})_2$, $-R^{21}-N(R^{20})C(O)OR^{22}$, $-R^{21}-N(R^{20})C(O)R^{22}$, $-R^{21}-N(R^{20})S(O)_pR^{22}$, $-R^{21}-N=C(OR^{20})R^{20}$, $-R^{21}-S(O)_pOR^{22}$, $-R^{21}-S(O)_tR^{22}$, and $-R^{21}-S(O)_pN(R^{20})_2$;

wherein:

each p is independently 1 to 2;

each t is independently 0 to 2;

each R^{20} is independently hydrogen, C_{1-12} alkyl, C_{1-12} haloalkyl, C_{3-15} cycloalkyl,

cycloalkylalkyl, C₆₋₁₈ aryl, aralkyl, 3-18 membered heterocyclyl, heterocyclalkyl, 5-14 membered heteroaryl, or heteroarylalkyl;
each R²¹ is independently a direct bond or a straight or branched C₁₋₁₂ alkylene chain;
and
each R²² is C₁₋₁₂ alkyl, C₁₋₁₂ haloalkyl, C₃₋₁₅ cycloalkyl, cycloalkylalkyl, C₆₋₁₈ aryl, aralkyl, 3-18 membered heterocyclyl, heterocyclalkyl, 5-14 membered heteroaryl or heteroarylalkyl.

2. The compound of Claim 1, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is -O-.

3. The compound of Claim 2, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

n is 1 or 2;

m is 1 or 2;

X is a direct bond or -C(R⁹)R¹⁰-;

Y is a direct bond or -C(R¹¹)R¹²-;

R¹ is alkyl, -R¹⁷-OR¹⁴, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted *N*-heterocyclyl, an optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an optionally substituted *S*-heteroaryl;

R² is an optionally substituted 5-membered *N*-heteroaryl or an optionally substituted 6-membered *N*-heteroaryl;

R⁴ and R⁵ are each independently hydrogen, alkyl or haloalkyl;

or R⁴ and R¹, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, and R⁵ is hydrogen, alkyl, haloalkyl or optionally substituted aryl;

each R⁶ is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, -OR¹⁴ or optionally substituted cycloalkyl;

R⁷ is alkyl, halo, haloalkyl, cyano or -OR¹⁴;

each R⁸ is independently hydrogen, alkyl, halo, haloalkyl or -OR¹⁴;

or two R⁸'s, together with the carbon to which they are both attached, may form an optionally substituted cycloalkyl;

R⁹, R¹⁰, R¹¹ and R¹² are each independently hydrogen, alkyl, haloalkyl, alkyl or -OR¹⁴; or R⁹ and R¹¹ form an optionally substituted alkylene chain; and each R¹⁴ are each independently hydrogen, alky, haloalkyl, optionally substituted aryl or optionally substituted aralkyl; and R¹⁷ is a direct bond or an optionally substituted alkylene chain.

4. The compound of Claim 3, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X and Y are both a direct bond.

5. The compound of Claim 4, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 5-membered *N*-heteroaryl.

6. The compound of Claim 5, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

7. The compound of Claim 6, which is 4-((1-benzylazetidin-3-yl)oxy)-3-chloro-*N*-(thiazol-2-yl)benzene-sulfonamide, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

8. The compound of Claim 4, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 6-membered *N*-heteroaryl.

9. The compound of Claim 8, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted pyridinyl.

10. The compound of Claim 3, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X is -C(R⁹)R¹⁰- and Y is a direct bond.

11. The compound of Claim 10, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 5-membered *N*-heteroaryl.

12. The compound of Claim 11, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

13. The compound of Claim 12, selected from:

(*S*)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-3-ethyl-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-3-bromo-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-2,6-difluoro-3-methyl-*N*-(thiazol-2-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-2,6-difluoro-*N*-(thiazol-4-yl)-3-vinylbenzenesulfonamide;

rac-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide; and

(*S*)-4-((1-benzylpyrrolidin-3-yl)oxy)-3-chloro-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or

a pharmaceutically acceptable salt or solvate thereof.

14. The compound of Claim 10, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is an optionally substituted 6-membered *N*-heteroaryl.

15. The compound of Claim 14, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is optionally substituted pyridinyl.

16. The compound of Claim 3, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X is $-C(R^9)R^{10}-$ and Y is $-C(R^{11})R^{12}-$.

17. The compound of Claim 16, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is an optionally substituted 5-membered *N*-heteroaryl.

18. The compound of Claim 17, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

19. The compound of Claim 18, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is optionally substituted aryl or optionally substituted aralkyl; and
 R^9 , R^{10} , R^{11} and R^{12} are each independently hydrogen or alkyl.

20. The compound of Claim 19, selected from:
5-chloro-2-fluoro-4-(1-(1-phenylethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
3-chloro-4-(1-(1-phenylethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
3-chloro-4-(1-(3-fluorobenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
3-chloro-4-(1-(3-(difluoromethyl)benzyl)piperidin-4-yloxy)-*N*-(thiazol-2-

yl)benzenesulfonamide;
 3-chloro-4-(1-(3-(difluoromethoxy)benzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-((6-methylpyridin-2-yl)methyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(3-methoxybenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(3-chlorobenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(2-fluorobenzyl)-3-methylpiperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(3-methyl-1-(3-methylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-(1-benzyl-3-methylpiperidin-4-yloxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(2-fluorobenzyl)-3-methylpiperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(3-methyl-1-(3-methylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-(1-benzyl-3-methylpiperidin-4-yloxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(naphthalen-2-ylmethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(2-fluorobenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(2-methylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(3-methylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(pyridin-2-ylmethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(pyridin-3-ylmethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(pyridin-4-ylmethyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(4-methoxybenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(3,4-dimethylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(3,5-dimethylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(1-(4-methylbenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-(1-benzylpiperidin-4-yloxy)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;

3-chloro-*N*-(thiazol-2-yl)-4-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yloxy)benzenesulfonamide;
 3-chloro-4-(1-(4-fluorobenzyl)piperidin-4-yloxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-(1-benzylpiperidin-4-yloxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(cyclohexylmethyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(cyclohexylpiperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-*N*-(thiazol-2-yl)-4-((1-(2-(trifluoromethyl)benzyl)piperidin-4-yl)oxy)benzenesulfonamide;
 3-chloro-4-((1-(2-chlorobenzyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-((4-methylpyridin-2-yl)methyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-((1-benzyl-4-methylpiperidin-4-yl)oxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(3-chlorobenzyl)-4-methylpiperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(3-(difluoromethyl)benzyl)-4-methylpiperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(2,3-dihydro-1*H*-inden-1-yl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-5-chloro-2-fluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*S*)-3-chloro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-((1-(2-phenylpropan-2-yl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 5-chloro-2-fluoro-4-((1-(2-phenylpropan-2-yl)piperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-2,3-difluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-2-fluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;

4-((1-benzylpiperidin-4-yl)oxy)-2-fluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)oxy)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 3-chloro-4-((1-(1-phenylcyclopropyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 5-chloro-4-(((3*R*,4*S*)-1-(3-(difluoromethyl)benzyl)-3-fluoropiperidin-4-yl)oxy)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-5-chloro-2-fluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(1-(5-chloro-2-fluorophenyl)ethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-2,6-difluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-*N*-(isoxazol-3-yl)-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)benzenesulfonamide;
 3-chloro-4-((1-phenethylpiperidin-4-yl)oxy)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(1-(2-fluoro-5-(trifluoromethyl)phenyl)ethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)oxy)-2,6-difluoro-3-methyl-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)oxy)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((*cis*-1-benzyl-2-methylpiperidin-4-yl)oxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-((*trans*-1-benzyl-2-methylpiperidin-4-yl)oxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide.
 (*R*)-3-chloro-4-((1-(1-(5-cyclopropyl-2-fluorophenyl)ethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(1-(5-(difluoromethyl)-2-fluorophenyl)ethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-2,6-difluoro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 3-chloro-4-((1-(3-(difluoromethyl)benzyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-5-chloro-2-fluoro-4-((1-(1-(2-fluoro-5-(trifluoromethyl)phenyl)ethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)oxy)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-2,6-difluoro-3-methyl-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)oxy)-3-chloro-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide; and
 4-((1-benzylpiperidin-4-yl)oxy)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or
 a pharmaceutically acceptable salt or solvate thereof.

21. The compound of Claim 18, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:
*R*¹ is optionally substituted aryl or optionally substituted aralkyl;
*R*⁹ and *R*¹¹ form an optionally substituted alkylene chain; and
*R*¹¹ and *R*¹² are each independently hydrogen or alkyl.

22. The compound of Claim 21, selected from:
 4-((1*R*,3*S*,5*S*)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-((1*R*,3*r*,5*S*)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yloxy)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-(((1*R*,3*S*,5*S*)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;
 5-chloro-4-(((1*R*,3*S*,5*S*)-8-(3-chlorobenzyl)-8-azabicyclo[3.2.1]octan-3-yl)oxy)-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(((1*R*,3*S*,5*S*)-8-(5-chloro-2-fluorobenzyl)-8-azabicyclo[3.2.1]octan-3-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-(((1*R*,3*S*,5*S*)-8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)-3-chloro-*N*-(thiazol-4-yl)benzenesulfonamide;
 3-chloro-4-(((1*R*,3*S*,5*S*)-8-(3-chloro-4-fluorobenzyl)-8-azabicyclo[3.2.1]octan-3-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide; and
 3-chloro-4-(((1*R*,3*S*,5*S*)-8-(3-(difluoromethyl)benzyl)-8-azabicyclo[3.2.1]octan-3-yl)oxy)-*N*-(thiazol-4-yl)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or
 a pharmaceutically acceptable salt or solvate thereof.

23. The compound of Claim 16, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 6-membered *N*-heteroaryl.

24. The compound of Claim 23, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted pyridinyl or optionally substituted pyrimidinyl.

25. The compound of Claim 24, selected from:

(*R*)-3-chloro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(pyrimidin-4-yl)benzenesulfonamide;

(*R*)-3-chloro-*N*-(5-fluoropyrimidin-2-yl)-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)benzenesulfonamide;

(*S*)-3-chloro-4-((1-(1-phenylethyl)piperidin-4-yl)oxy)-*N*-(pyrimidin-4-yl)benzenesulfonamide;

4-((1-benzylpiperidin-4-yl)oxy)-3-chloro-*N*-(6-fluoropyridin-2-yl)benzenesulfonamide;

and

4-((1-benzylpiperidin-4-yl)oxy)-5-chloro-2-fluoro-*N*-(6-fluoropyridin-2-yl)benzenesulfonamide;

as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

26. The compound of Claim 1, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is -N(R¹³)-.

27. The compound of Claim 26, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

n is 1 or 2;

m is 1 or 2;

X is a direct bond or -C(R⁹)R¹⁰-;

Y is a direct bond or -C(R¹¹)R¹²-;

R¹ is alkyl, -R¹⁷-OR¹⁴, an optionally substituted cycloalkyl, an optionally substituted aryl,

an optionally substituted aralkyl, an optionally substituted *N*-heterocyclyl, an optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an optionally substituted *S*-heteroaryl;

R² is an optionally substituted 5-membered *N*-heteroaryl or an optionally substituted 6-membered *N*-heteroaryl;

R⁴ and R⁵ are each independently hydrogen, alkyl or haloalkyl;

or R⁴ and R¹, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, and R⁵ is hydrogen, alkyl, haloalkyl or optionally substituted aryl;

each R⁶ is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, -OR¹⁴ or optionally substituted cycloalkyl;

R⁷ is alkyl, halo, haloalkyl, cyano or -OR¹⁴;

each R⁸ is independently hydrogen, alkyl, halo, haloalkyl or -OR¹⁴;

or two R⁸'s, together with the carbon to which they are both attached, may form an optionally substituted cycloalkyl;

R⁹, R¹⁰, R¹¹ and R¹² are each independently hydrogen, alkyl, haloalkyl, alkyl or -OR¹⁴;

or R⁹ and R¹¹ form an optionally substituted alkylene chain

R¹³ is hydrogen, alkyl or haloalkyl;

each R¹⁴ are each independently hydrogen, alky, haloalkyl, optionally substituted aryl or optionally substituted aralkyl; and

R¹⁷ is a direct bond or an optionally substituted alkylene chain.

28. The compound of Claim 27, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X and Y are both a direct bond.

29. The compound of Claim 28, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 5-membered *N*-heteroaryl.

30. The compound of Claim 29, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

31. The compound of Claim 30, selected from:
4-((1-benzyl-3-methylazetidin-3-yl)amino)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
4-((1-benzyl-3-methylazetidin-3-yl)amino)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
4-((1-benzyl-3-methylazetidin-3-yl)amino)-3-chloro-*N*-(thiazol-4-yl)benzenesulfonamide;
4-((1-benzyl-3-methylazetidin-3-yl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide; and
4-((1-benzylazetidin-3-yl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or
a pharmaceutically acceptable salt or solvate thereof.

32. The compound of Claim 28, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 6-membered *N*-heteroaryl.

33. The compound of Claim 32, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted pyridinyl.

34. The compound of Claim 27, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X is -C(R⁹)R¹⁰- and Y is a direct bond.

35. The compound of Claim 34, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 5-membered *N*-heteroaryl.

36. The compound of Claim 35, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

37. The compound of Claim 36, as an individual stereoisomer, enantiomer,

or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted thiadiazolyl.

38. The compound of Claim 37, selected from:

- (S)-3-chloro-4-((1-(3,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-4-((1-(2,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-4-((1-(2,6-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-4-((1-(2-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-2,6-difluoro-3-methyl-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-2,6-difluoro-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-4-(ethyl(1-(3-methylbenzyl)pyrrolidin-3-yl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-4-((1-benzylpyrrolidin-3-yl)(ethyl)amino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-3-chloro-4-(methyl(1-(3-methylbenzyl)pyrrolidin-3-yl)amino)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (R)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (S)-4-(1-benzylpyrrolidin-3-ylamino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- (R)-4-(1-benzylpyrrolidin-3-ylamino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
- 4-(1-benzylpyrrolidin-3-ylamino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(3-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(3-chloro-2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(5-chloro-2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(2-fluoro-3-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide; and

(S)-3-chloro-4-((1-(2-fluoro-5-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;

as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

39. The compound of Claim 36, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ is optionally substituted aryl or optionally substituted aralkyl; and

R² is optionally substituted thiazolyl or isoxazolyl.

40. The compound of Claim 39, selected from:

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-bromo-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(3-(2-hydroxypropan-2-yl)benzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(5-chloro-2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(2-fluoro-4-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-(3-phenylpropyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-

(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(2-hydroxybenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(3-hydroxybenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-4-((1-benzylpyrrolidin-3-yl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(3-(difluoromethoxy)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-cyclopropyl-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(2,5-dichlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

5-chloro-2-fluoro-4-(methyl((*S*)-1-((*R*)-1-phenylpropyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-(4-propylbenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(2-fluoro-5-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-(2-phenylpropan-2-yl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

3-chloro-4-(methyl((*S*)-1-((*R*)-1-phenylethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-phenethylpyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(isothiazol-3-yl)-5-methylbenzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-*N*-(isothiazol-3-yl)-3-methylbenzenesulfonamide;

(S)-2-fluoro-4-((1-(2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(ethyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

methyl (S)-3-((3-((2-chloro-5-fluoro-4-(*N*-(thiazol-4-yl)sulfamoyl)phenyl)(methyl)amino)pyrrolidin-1-yl)methyl)benzoate;

(S)-5-chloro-4-((1-(2-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(4-(dimethylamino)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(ethyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzyl-3-methylpyrrolidin-3-yl)amino)-3-chloro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(5-chloro-2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-bromo-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(3-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-ethyl-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(3-isopropoxybenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-(4-methylbenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(2,6-dimethylbenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(3-fluoro-2-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-phenethylpyrrolidin-3-yl)amino)-*N*-(thiazol-4-

yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(3-chloro-2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(2-methoxybenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(4-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

4-(((2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

3-chloro-4-(methyl((S)-1-((S)-1-phenylethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2,3-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2,3-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2,6-difluoro-4-((1-(2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(2,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(3-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(2-fluoro-5-methylbenzyl)-3-methylpyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,5-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(2-methoxybenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

4-(((3S,5S)-1-benzyl-5-methylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

5-chloro-4-(((*S*)-1-((*S*)-1-(2-chlorophenyl)propyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-4-((1-(2-(difluoromethoxy)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-(4-fluoro-3-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

5-chloro-2-fluoro-4-(methyl((*S*)-1-((*S*)-1-phenylpropyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

4-((1-benzyl-3-methylpyrrolidin-3-yl)(methyl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;

(*S*)-5-chloro-4-((1-(4-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-4-((1-benzylpyrrolidin-3-yl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(isothiazol-4-yl)-5-methylbenzenesulfonamide;

(*S*)-2,6-difluoro-4-((1-(3-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*R*)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-(difluoromethyl)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-(methyl(1-(2-methylbenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-(2-hydroxybenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-(3-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-4-((1-(2,3-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-(methyl(1-(3-(trifluoromethyl)benzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-(2-fluoro-3-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(2-fluoro-5-methoxybenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide;

(R)-4-((1-benzyl-3-methylpyrrolidin-3-yl)amino)-3-chloro-N-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-(2-methylbenzyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(4-hydroxybenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-N-(thiazol-4-yl)-3-(trifluoromethyl)benzenesulfonamide;

(S)-2-fluoro-4-((1-(2-fluoro-3-methylbenzyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2,5-difluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-3-methyl-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(4-bromobenzyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(2-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(3-methoxybenzyl)pyrrolidin-3-yl)(methyl)amino)-N-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-(2-chloro-6-fluorobenzyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide;

(S)-3-chloro-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((5-benzyl-5-azaspiro[2.4]heptan-7-yl)amino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((5-benzyl-5-azaspiro[2.4]heptan-7-yl)(methyl)amino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-2,6-difluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-4-(1-benzylpyrrolidin-3-ylamino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-5-chloro-2-fluoro-4-(1-(3-methylbenzyl)pyrrolidin-3-ylamino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-4-(1-benzylpyrrolidin-3-ylamino)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-5-chloro-2-fluoro-4-(1-(3-methylbenzyl)pyrrolidin-3-ylamino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (*R*)-4-(1-benzylpyrrolidin-3-ylamino)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-3-chloro-4-((1-(3-chlorobenzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-3-chloro-4-((1-(3-(difluoromethyl)benzyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-3-chloro-*N*-(thiazol-4-yl)benzenesulfonamide;
 3-chloro-4-(methyl((*S*)-1-((*S*)-1-phenylethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 3-chloro-4-(methyl((*S*)-1-((*R*)-1-phenylethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;
 4-((1-benzyl-3-methylpyrrolidin-3-yl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;
 (S)-3-chloro-4-(methyl(1-(2-phenylpropan-2-yl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (*R*)-3-chloro-4-((1-(3-chlorobenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;

(*R*)-3-chloro-4-((1-(3-methylbenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;

(*R*)-3-chloro-4-((1-(2-fluorobenzyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-2-yl)benzenesulfonamide;

4-((*trans*-1-benzyl-4-methylpyrrolidin-3-yl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide;

4-((*cis*-1-benzyl-4-methylpyrrolidin-3-yl)amino)-3-chloro-*N*-(thiazol-2-yl)benzenesulfonamide; and

(*S*)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(isoxazol-3-yl)-5-methylbenzenesulfonamide;

as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

41. The compound of Claim 36, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ is an optionally substituted *N*-heterocyclyl, an optionally substituted *N*-heteroaryl, an optionally substituted *O*-heteroaryl or an optionally substituted *S*-heteroaryl; and

R² is optionally substituted thiazolyl.

42. The compound of Claim 41, selected from:

(*S*)-4-((1-((1,4-dimethyl-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((4-methylthiazol-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-(pyridin-2-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((2-methylthiazol-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((1-methyl-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-4-((1-((3-fluoro-6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-

5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-((1-benzyl-1H-pyrazol-4-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-(methyl(1-((5-(trifluoromethyl)furan-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((2-methyloxazol-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((5-methylfuran-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-4-((1-((2-isopropoxyloxazol-4-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-((6-methoxypyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-((1-((3-fluoro-6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-5-chloro-2-fluoro-4-(methyl(1-(quinolin-8-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-((4-cyclopropylthiazol-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-((6-(azetidin-1-yl)pyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((2-phenylthiazol-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-(thiazol-2-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((2-(trifluoromethyl)thiazol-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-4-((1-((2-cyclopropylthiazol-4-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-5-methyl-4-(methyl(1-((4-methyloxazol-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-4-((1-((3-isopropoxyypyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(*S*)-2-fluoro-4-((1-((3-fluoro-6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-3-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-((3-methoxypyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((6-bromopyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1H-pyrrol-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((5-methylfuran-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-(thiazol-4-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-3-chloro-2,6-difluoro-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((1-methyl-1H-pyrrol-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1H-indol-3-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-((5-(trifluoromethyl)furan-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-(oxazol-4-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-((3-methoxypyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((1-methyl-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(imidazo[1,5-a]pyridin-3-ylmethyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((2-(trifluoromethyl)pyridin-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-((6-(difluoromethyl)pyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-((1-(isoquinolin-8-ylmethyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((6-(trifluoromethyl)pyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-((2-isopropylthiazol-4-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(benzo[d]thiazol-2-ylmethyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-((5-methylisothiazol-3-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-(pyrazolo[1,5-a]pyridin-2-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1H-indol-5-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-(thiophen-2-ylmethyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((4-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-4-((1-((4-isopropylthiazol-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((5-chlorothiazol-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2,6-difluoro-3-methyl-4-(methyl(1-((6-(trifluoromethyl)pyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-4-((1-((6-(difluoromethyl)-3-fluoropyridin-2-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-5-chloro-2-fluoro-4-(methyl(1-((5-methylthiophen-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((1-(2,2-difluoroethyl)-1H-pyrazol-3-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-2-fluoro-5-methyl-4-(methyl(1-((2-methyl-5-(trifluoromethyl)oxazol-4-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-((2,5-dimethyloxazol-4-yl)methyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-2-fluoro-5-methyl-4-(methyl(1-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-2-fluoro-5-methyl-4-(methyl(1-((4-(trifluoromethyl)thiazol-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide; and
 (S)-2,6-difluoro-3-methyl-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

43. The compound of Claim 36, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ is alkyl, -R¹⁷-OR¹⁴ or an optionally substituted cycloalkyl; and
 R⁴ and R⁵ are each independently hydrogen, alkyl or haloalkyl;
 or R⁴ and R¹, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, and R⁵ is hydrogen, alkyl, haloalkyl or optionally substituted aryl.

44. The compound of Claim 43, selected from:
 2-fluoro-5-methyl-4-(methyl((S)-1-((1*S*,3*R*)-3-phenylcyclobutyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-5-chloro-4-((1-(2,3-dihydro-1*H*-inden-2-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-5-chloro-2-fluoro-4-(methyl(1-(1-phenylcyclopropyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-4-((1-(2,3-dihydro-1*H*-inden-2-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-5-chloro-4-((1-(3,3-dimethylbutyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-(((S)-1-((S)-2,3-dihydro-1*H*-inden-1-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-5-chloro-2-fluoro-4-((1-(1-(2-fluorophenyl)cyclobutyl)pyrrolidin-3-yl)(methyl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;

(S)-4-((1-(2-(benzyloxy)ethyl)pyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 5-chloro-4-(((S)-1-((R)-2,3-dihydro-1H-inden-1-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 2-fluoro-5-methyl-4-(methyl((S)-1-((1*r*,3*S*)-3-phenylcyclobutyl)pyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-4-((1-(cyclohexylmethyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 3-chloro-4-(((S)-1-((S)-2,3-dihydro-1H-inden-1-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 5-chloro-4-(((S)-1-((S)-2,3-dihydro-1H-inden-1-yl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(thiazol-4-yl)benzenesulfonamide;
 (S)-2-fluoro-5-methyl-4-(methyl(1-neopentylpyrrolidin-3-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide; and
 (S)-4-((1-(3,3-dimethylbutyl)pyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-*N*-(thiazol-4-yl)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

45. The compound of Claim 34, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 6-membered *N*-heteroaryl.

46. The compound of Claim 45, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted pyridinyl.

47. The compound of Claim 46, selected from:
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-*N*-(5-fluoropyridin-2-yl)-3-methylbenzenesulfonamide;
 (S)-5-chloro-2-fluoro-*N*-(6-fluoropyridin-2-yl)-4-(methyl(1-(2-phenylpropan-2-yl)pyrrolidin-3-yl)amino)benzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-*N*-(6-fluoropyridin-2-yl)-3-methylbenzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(5-fluoropyridin-2-yl)-5-

methylbenzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-*N*-(6-fluoropyridin-2-yl)-5-methylbenzenesulfonamide;
 (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(6-fluoropyridin-2-yl)benzenesulfonamide;
 3-chloro-2-fluoro-*N*-(6-fluoropyridin-2-yl)-4-(((S)-1-((S)-1-phenylethyl)pyrrolidin-3-yl)amino)benzenesulfonamide; and
 5-chloro-2-fluoro-*N*-(6-fluoropyridin-2-yl)-4-(methyl((S)-1-((R)-1-phenylethyl)pyrrolidin-3-yl)amino)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

48. The compound of Claim 27, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein X is -C(R⁹)R¹⁰- and Y is -C(R¹¹)R¹²-.

49. The compound of Claim 48, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 5-membered *N*-heteroaryl.


50. The compound of Claim 49, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted isoxazolyl, optionally substituted thiazolyl or optionally substituted thiadiazolyl.

51. The compound of Claim 50, selected from:
 (R)-5-chloro-2-fluoro-4-(methyl(1-(1-phenylethyl)piperidin-4-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 (R)-2-fluoro-5-methyl-4-(methyl(1-(1-phenylethyl)piperidin-4-yl)amino)-*N*-(thiazol-4-yl)benzenesulfonamide;
 4-((1-benzylpiperidin-4-yl)(methyl)amino)-5-chloro-2-fluoro-*N*-(thiazol-2-yl)benzenesulfonamide; and
 4-(1-benzylpiperidin-4-ylamino)-3-chloro-*N*-(1,2,4-thiadiazol-5-yl)benzenesulfonamide;
 as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof.

52. The compound of Claim 48, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is an optionally substituted 6-membered *N*-heteroaryl.


53. The compound of Claim 52, as an individual stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof, wherein R² is optionally substituted pyridinyl.

54. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

55. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

56. A compound, which is (S)-2,6-difluoro-3-methyl-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

57. A compound, which is (S)-4-((1-benzyl-3-methylpyrrolidin-3-yl)oxy)-2,6-difluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

58. A compound, which is (S)-3-chloro-2,6-difluoro-4-(methyl(1-((6-methylpyridin-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

59. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-N-(isothiazol-3-yl)-5-methylbenzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

60. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-N-(isothiazol-3-yl)-3-methylbenzenesulfonamide, represented by the formula:




or a pharmaceutically acceptable salt or solvate thereof.

61. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2,6-difluoro-N-(6-fluoropyridin-2-yl)-3-methylbenzenesulfonamide, represented by the formula:



or a pharmaceutically acceptable salt or solvate thereof.

62. A compound, which is (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-3-methyl-N-(thiazol-4-yl)benzenesulfonamide, represented by the formula:



or a pharmaceutically acceptable salt or solvate thereof.

63. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of Claims 1-53, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof.

64. A compound of any one of Claims 1-53, as a stereoisomer, enantiomer

or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof, for use in treating a disease or a condition associated with Na_v1.6 activity in a mammal, wherein the disease or condition is epilepsy and/or epileptic seizure disorder.

65. An *in vitro* method of decreasing ion flux through Na_v1.6 in a mammalian cell, wherein the method comprises contacting the cell with a compound of any one of Claims 1-53, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof.

66. A compound of any one of Claims 1-53, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof, for use in selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal.

67. The compound of Claim 66, wherein the first voltage-gated sodium channel is Na_v1.6.

68. The compound of Claim 67, wherein the second voltage-gated sodium channel is Na_v1.5.

69. The compound of Claim 67, wherein the second voltage-gated sodium channel is Na_v1.1.

70. Use of a compound of any one of Claims 1-53, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a disease or a condition associated with Na_v1.6 activity in a mammal, wherein the disease or condition is epilepsy and/or epileptic seizure disorder.

71. Use of a compound of any one of Claims 1-53, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt or solvate thereof; or the compound of any one of claims 54-62, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal.

72. The use of Claim 71, wherein the first voltage-gated sodium channel is Na_v1.6.

73. The use of Claim 72, wherein the second voltage-gated sodium channel is Na_v1.5.

74. The use of Claim 72, wherein the second voltage-gated sodium channel is Na_v1.1.